ProCure proton centers select RayStation® for proton planning

        Print
| Source: RaySearch Laboratories AB
RaySearch Laboratories AB (publ.) has received two orders for its RayStation®
treatment planning system from the proton treatment centers Seattle ProCure
Management LLC in Seattle, Washington, and Princeton ProCure Management LLC in
Princeton, New Jersey. The two centers will use RayStation® for treatment
planning of proton radiation therapy.

Tony Wong, Director of Physics at the Seattle ProCure Treatment Center and
Dennis Mah, Director of Physics at the New Jersey ProCure Treatment Center,
comment: “There are several reasons why we selected RayStation®. The most
important benefits are the breadth of technology, high speed of planning and
dose computation and ease of analysis compared to other modalities. This is the
best system currently available in terms of robust optimization, computational
accuracy and ease of use.”

Marc Mlyn, President of RaySearch Americas, adds: “ProCure is a well-known name
in proton therapy, and given the strong partnerships between RaySearch, IBA and
now Procure, we are confident that this is a big step forward for all of us and
how proton planning can evolve. We are looking forward to a long and mutually
beneficial partnership with ProCure Management.”

“ProCure is an organization focused on quality of care and efficient
technologies. We see RaySearch as a good partner for us now and into the future,
and we plan on working with them to achieve our corporate vision for improving
the lives of patients with cancer by increasing access to proton therapy”, says
Howard Rubin, Senior Vice President of Information Systems at ProCure.

“These orders further cement our position as the leading supplier of treatment
planning software for particle therapy. Together with our customers and our
partner IBA, we will continue to refine our tools for proton and carbon ion
therapy to fully utilize the unique technical properties of these treatment
techniques to enable cancer treatments of the highest precision”, says Johan
Löf, CEO of RaySearch Laboratories.

The current version of RayStation® that has FDA clearance supports the proton
treatment techniques Uniform Scanning and Double Scattering. Support for PBS /
IMPT has been released in Europe with CE marking and 510(k) clearance in the US
for PBS is expected in early 2014.

About RayStation®
RayStation® integrates all RaySearch’s advanced treatment planning solutions
into a flexible treatment planning system. It combines unique features such as
multi-criteria optimization tools with full support for 4D adaptive radiation
therapy. It also includes functionality such as RaySearch’s market-leading
algorithms for IMRT and VMAT optimization and highly accurate dose engines for
photon, electron and proton therapy. The system is built on the latest software
architecture and has a graphical user interface offering state-of-the-art
usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch’s
products are mainly sold through license agreements with leading partners such
as Philips, Nucletron, IBA, Varian, Accuray and Brainlab. To date, 15 products
have been launched through partners and RaySearch’s software is used at over
2,300 clinics in more than 30 countries. In addition, RaySearch offers the
proprietary treatment planning system RayStation® directly to clinics. RaySearch
was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and
the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com


For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ.)
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com